BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23264397)

  • 1. Autoantibodies to the IGF1 receptor in Graves' orbitopathy.
    Minich WB; Dehina N; Welsink T; Schwiebert C; Morgenthaler NG; Köhrle J; Eckstein A; Schomburg L
    J Clin Endocrinol Metab; 2013 Feb; 98(2):752-60. PubMed ID: 23264397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
    Krieger CC; Neumann S; Gershengorn MC
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
    Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
    J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.
    Kahaly GJ; Wüster C; Olivo PD; Diana T
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2561-2568. PubMed ID: 30753531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
    Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
    Wiersinga WM
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy.
    Varewijck AJ; Boelen A; Lamberts SW; Fliers E; Hofland LJ; Wiersinga WM; Janssen JA
    J Clin Endocrinol Metab; 2013 Feb; 98(2):769-76. PubMed ID: 23295466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin receptor antibodies and Graves' orbitopathy.
    Diana T; Ponto KA; Kahaly GJ
    J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonistic Autoantibodies to Insulin-Like Growth Factor-1 Receptor Associate with Poor Physical Strength.
    Schwiebert C; Kühnen P; Becker NP; Welsink T; Keller T; Minich WB; Wiegand S; Schomburg L
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
    Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
    Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
    Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
    Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
    Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
    Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study.
    Diana T; Brown RS; Bossowski A; Segni M; Niedziela M; König J; Bossowska A; Ziora K; Hale A; Smith J; Pitz S; Kanitz M; Kahaly GJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1648-55. PubMed ID: 24517152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?
    Gopinath B; Wescombe L; Nguyen B; Wall JR
    Orbit; 2009; 28(4):256-61. PubMed ID: 19839885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease.
    Noh J; Hamada N; Saito H; Oyanagi H; Ishikawa N; Momotani N; Ito K; Morii H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):107-13. PubMed ID: 2909548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.
    Cheng KC; Wu YJ; Cheng KH; Cheng KY; Chen KJ; Wu WC; Lee PY; Chang CH
    Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1195-1201. PubMed ID: 29397435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.